Calibration recordkeeping is where a lot of otherwise-solid quality systems quietly fall apart. A missing due date or a maintenance step done in the wrong order can turn a routine FDA inspection into a Form 483 observation — and, left unresolved, a warning letter. Here’s what FY2025 enforcement data and two real warning letters reveal, and what an audit-ready system looks like.
Key Takeaways
Medical device warning letters citing Quality System Regulation failures jumped from 6 in 2021 to 30 in 2025 — a five-fold increase (Emergo by UL, 2025).
21 CFR 211.160, covering equipment suitability, was cited 33 times across 135 FY2025 drug-manufacturing warning letters (ELIQUENT Life Sciences, 2026).
Left unaddressed, these gaps escalate — consent decrees tied to quality-system failures have cost manufacturers $175 million to $500 million.
In 2025, the FDA issued 54 warning letters to medical device manufacturers — about 8% of the 695 sent across all industries that year (Emergo by UL, “US FDA CDRH Warning Letters: A Review of 2025”, 2025/2026). Device-specific Quality System Regulation letters climbed from 6 in 2021 to 30 in 2025, a five-fold increase — and equipment calibration falls squarely under 21 CFR 820.72(a), one of the sections driving that growth.
211.160, the lab-controls section covering equipment suitability, was cited 33 times across 135 FY2025 drug-manufacturing letters analyzed (Pharmaceutical Online / ELIQUENT Life Sciences, March 2026) — roughly one in four letters touched equipment or lab-control issues in some form. Calibration recordkeeping isn’t the single biggest line item on an FDA letter. It’s the recurring one.
What Inspectors Actually Cite: Two Real Warning Letters
Statistics show the pattern. Real warning letters show what it looks like on the floor.
Dr. Reddy’s Laboratories received an FDA Form 483 in late 2023 after inspectors found lab equipment used in commercial release “not meeting the calibration specifications.” The deeper issue was procedural: the firm’s SOP called for maintenance before calibration, letting equipment be adjusted right before the check — making it impossible to confirm accuracy through the prior cycle (ECA Academy, January 2024).
Global Medical Technology SL was cited in a 2019 warning letter for failing to routinely calibrate equipment under 21 CFR 820.72(a): its light energy tester was last calibrated in 2015, due again in 2016, and never recalibrated on schedule (FDA.gov Warning Letters database, 2019).
The common thread is a broken traceability chain. See our guide to NIST traceability in calibration.
What FDA Regulations Require for Calibration Records
21 CFR 820.72(a) requires medical device manufacturers to “establish and maintain procedures to ensure equipment is routinely calibrated, inspected, checked, and maintained” so it’s “capable of producing valid results” (21 CFR 820.72, current as of 2026). Drug manufacturers face the parallel requirement under 211.160.
ISO/IEC 17025:2017 requires an “unbroken chain of calibrations” back to national standards, each link reporting its own uncertainty (ISO/IEC 17025:2017). In practice, that chain most often breaks at the reference standard’s own certificate, not the production instrument’s. If ISO 13485 governs your device line, see our guide to ISO 13485 calibration requirements.
What Happens When These Gaps Go Unaddressed?
A warning letter is a warning. Ignore the underlying gaps and the next step is a consent decree — dramatically more expensive. Genzyme’s 2010 consent decree cost the company $175 million in surrendered profits (Manufacturing Chemist, 2010). Ranbaxy’s 2012 consent decree cost an estimated $500 million in remediation (Fierce Biotech, 2012).
Cost of Letting Quality Gaps Escalate
Quality teams rarely start out cutting corners on calibration recordkeeping — the gaps creep in through inconsistent spreadsheets, missing calibration stickers, or a certificate that never made it into the file.
How to Build an Audit-Ready Calibration Recordkeeping System
Fixing calibration recordkeeping isn’t about buying new instruments. It’s about closing the gaps the FDA keeps citing:
- Fix the sequence. Calibrate before preventive maintenance, not after — reversing that order breaks the audit trail.
- Set and document a frequency for every instrument — don’t calibrate “when it seems due.”
- Centralize records instead of scattering them across spreadsheets, so every certificate and out-of-tolerance investigation lives in one place.
Our guide to calibration management software and CMMS covers how to centralize that documentation before an inspector ever asks for it.
Need an ISO/IEC 17025-accredited calibration partner?
Micro Precision supports FDA-regulated manufacturers with accredited calibration, full traceability documentation, and digital certificates built for audits — not just for filing.
Frequently Asked Questions
Equipment used past its due date with no documented frequency. 21 CFR 211.160 was cited 33 times across 135 FY2025 letters, and 820.72(a) drove much of the five-fold rise in device QSR letters since 2021.
FDA rules require equipment “capable of producing valid results,” which in practice means traceability. ISO/IEC 17025:2017 requires an unbroken, documented chain of calibrations back to national standards.
A Form 483 lists inspection observations, like the calibration gap cited at Dr. Reddy’s. A warning letter follows when the FDA finds the company’s response inadequate, as with Global Medical Technology SL.
Conclusion
Calibration recordkeeping failures rarely start as headline incidents. They start as a missed due date or an unfiled certificate — and FDA data shows inspectors are finding them more often. Manufacturers serving FDA-regulated medical and biomedical industries can close most gaps with centralized records, a verified traceability chain, and a partner willing to document both.